Shionogi Acquires Maze’s Pompe Disease Drug Following FTC’s Sanofi Deal Halt

1. Shionogi, a Japanese pharmaceutical company, has secured a deal to acquire Maze's Pompe disease drug for $150 million.
2. The deal comes after the U.S. Federal Trade Commission (FTC) stalled Sanofi's acquisition of the same drug due to antitrust concerns.
3. Pompe disease is a rare genetic disorder that affects the muscles and can lead to respiratory failure and heart problems.
4. Maze's drug is a potential treatment for Pompe disease and has shown promising results in clinical trials.
5. Shionogi's acquisition of the drug will allow the company to expand its portfolio of rare disease treatments and potentially bring a new therapy to patients with Pompe disease.
6. The deal is expected to close in the second half of 2023, pending regulatory approval.
7. The acquisition highlights the growing interest in the development of treatments for rare diseases, as well as the increasing competition in the pharmaceutical industry.